Amphotericin B deoxycholate administered by continuous infusion: Does the dosage make a difference?

Clinical Infectious Diseases

Volumn 36, Issue 8, 2003, Pages 952-953

  Hiemenz, John W ^a  

^a MEDICAL COLLEGE OF GEORGIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AMPHOTERICIN B CHOLESTEROL SULFATE; AMPHOTERICIN B DEOXYCHOLATE; AMPHOTERICIN B LIPID COMPLEX; ANIDULAFUNGIN; CASPOFUNGIN; GAMMA INTERFERON; MICAFUNGIN; POSACONAZOLE; RAVUCONAZOLE; TRIAZOLE DERIVATIVE; VORICONAZOLE; AMPHOTERICIN B; AMPHOTERICIN B-DEOXYCHOLATE; DEOXYCHOLIC ACID; DRUG DERIVATIVE;

ASPERGILLOSIS; CLINICAL PROTOCOL; CLINICAL TRIAL; CONTINUOUS INFUSION; CRITICAL ILLNESS; DOSE RESPONSE; DRUG DELIVERY SYSTEM; DRUG DOSE REGIMEN; DRUG EFFICACY; DRUG FORMULATION; DRUG SAFETY; DRUG TOLERABILITY; DRUG UTILIZATION; EDITORIAL; HUMAN; IMMUNE DEFICIENCY; MYCOSIS; NEPHROTOXICITY; NEUTROPENIA; NONHUMAN; OUTCOMES RESEARCH; PRIORITY JOURNAL; SURVIVAL RATE; TECHNIQUE; ANIMAL; ANIMAL MODEL; CHEMISTRY; DRUG COMBINATION; DRUG EFFECT; INFUSION PUMP; KIDNEY; NOTE;

AMPHOTERICIN B; ANIMALS; CHEMISTRY, PHARMACEUTICAL; DEOXYCHOLIC ACID; DRUG COMBINATIONS; HUMANS; INFUSION PUMPS; KIDNEY; MODELS, ANIMAL;

EID: 0037445548     PISSN: 10584838     EISSN: None     Source Type: Journal    
DOI: 10.1086/368317     Document Type: Editorial

References (13)

1. Walsh TJ, Finberg RW, Arndt C, et al. Liposomal amphotericin B for empirical therapy in patients with persistent fever and neutropenia. N Engl J Med 1999; 340:764-71.
2. Prentice HG, Hann IM, Herbrecht R, et al. A randomized comparison of liposomal versus conventional amphotericin B in the treatment of pyrexia of unknown origin in neutropenic patients. Br J Haematol 1997; 98:711-98.
3. White MH, Bowden RA, Sandler ES, et al. Randomized, double-blind clinical trial of amphotericin B colloidal dispersion vs. amphotericin B in the empirical treatment of fever and neutropenia. Clin Infect Dis 1998; 27:296-302.
4. Luke RG, Boyle T. Renal effects of amphotericin B lipid complex. Am J Kidney Dis 1998; 31:780.
5. Eriksson U, Seifert B, Schaffner A. Comparison of effects of amphotericin B deoxycholate infused over 4 or 24 hours: randomised controlled trial. BMJ 2001; 322:579-82.
6. Imhof A, Walter RB, Schaffner A. Continuous infusion of escalated amphotericin B deoxycholate: an open-label observational study. Clin Infect Dis 2003; 36:943-51 (in this issue).
7. Hiemenz JW, Walsh TJ. Lipid formulations of amphotericin B: recent progress and future directions. Clin Infect Dis 1996; 22(Suppl 2):S133-44.
8. Allende MC, Lee JW, Francis P, et al. Dose-dependent antifungal activity and nephrotoxicity of amphotericin B colloidal dispersion in experimental pulmonary aspergillosis. Antimicrob Agents Chemother 1994; 38:518-22.
9. Francis P, Lee JW, Hoffman A, et al. Efficacy of unilamellar liposomal amphotericin B in treatment of pulmonary aspergillosis in persistently granulocytopenic rabbits: the potential role of bronchoalveolar D-mannitol and serum galactomannan as markers of infection. J Infect Dis 1994; 169:356-68.
10. Walsh TJ, Hiemenz JW, Seibel NL, et al. Amphotericin B lipid complex for invasive fungal infections: analysis of safety and efficacy in 556 cases. Clin Infect Dis 1998; 26:1383-96.
11. Walsh TJ, Goodman JL, Pappas P, et al. Safety, tolerance, and pharmacokinetics of high-dose liposomal amphotericin B (AmBisome) in patients infected with Aspergillus species and other filamentous fungi: maximum tolerated dose study. Antimicrob Agents Chemother 2001; 45:3487-96.
12. Bowden R, Chandrasekar P, White MH, et al. A double-blind randomized, controlled trial of amphotericin B colloidal dispersion versus amphotericin B for treatment of invasive aspergillosis in immunocompromised patients. Clin Infect Dis 2002; 35:359-66.
13. Ellis M, Spence D, de Pauw B, et al. An EORTC international multicenter randomized trial (EORTC number 19923) comparing two dosages of liposomal amphotericin B for treatment of invasive aspergillosis. Clin Infect Dis 1998; 27:1406-12.